|
18 Companies |
|
18 Products |
|
18 Products |
|
16 Mechanisms of Action |
|
0 Trials |
|
206 News |
|
| «1234» |
- Rotarix (rotavirus vaccine) / GSK
Trial completion: Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines (clinicaltrials.gov) - Aug 27, 2013
P4, N=620, Completed, Sponsor: Program for Appropriate Technology in Health
Active, not recruiting --> Completed
- Trial completion, HEOR: Glutathione and Health With Post-Polio Syndrome (clinicaltrials.gov) - Aug 19, 2013
P=N/A, N=19, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: IPV Clinical Trial - The Gambia (clinicaltrials.gov) - Jul 14, 2013
P4, N=1504, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
Recruiting --> Completed Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jul 9, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (clinicaltrials.gov) - May 15, 2013
P4, N=1420, Recruiting, Sponsor: Fidec Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | New P4 trial: IPV Clinical Trial - The Gambia (clinicaltrials.gov) - May 5, 2013
P4, N=1504, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P2 trial: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - May 1, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- | New P4 trial: Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (clinicaltrials.gov) - Apr 11, 2013
P4, N=1420, Recruiting, Sponsor: Fidec Corporation
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial termination: HAM06: The HAM Infliximab Study (clinicaltrials.gov) - Apr 11, 2013
P2, N=3, Terminated, Sponsor: Imperial College London
Not yet recruiting --> Recruiting Recruiting --> Terminated; Higher toxicity rate than observed in studies in Rheumatoid arthritis
- |||| Trial completion: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Apr 9, 2013
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
Recruiting --> Terminated; Higher toxicity rate than observed in studies in Rheumatoid arthritis Active, not recruiting --> Completed
- ||||||| Trial completion: Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan (clinicaltrials.gov) - Mar 27, 2013
P3, N=74, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial completion: A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China (clinicaltrials.gov) - Mar 27, 2013
P4, N=5007, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial: Immunogenicity of Inactivated and Live Polio Vaccines (clinicaltrials.gov) - Mar 17, 2013
P3, N=1206, Completed, Sponsor: Centers for Disease Control and Prevention
- Rotarix (rotavirus vaccine) / GSK
Enrollment closed: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh (clinicaltrials.gov) - Mar 3, 2013
P1, N=700, Active, not recruiting, Sponsor: University of Vermont
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
New P2 trial: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jan 24, 2013
P2, N=10, Recruiting, Sponsor: Johns Hopkins University
- Trial withdrawal: Diarrhea and Bivalent Oral Polio Vaccine Immunity (clinicaltrials.gov) - Jan 2, 2013
P3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Diarrhea and Bivalent Oral Polio Vaccine Immunity (clinicaltrials.gov) - Jan 2, 2013
P3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
Not yet recruiting --> Withdrawn N=900 --> 0
- Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
New P1 trial: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) - Jan 1, 2013
P1, N=10, Completed, Sponsor: Michael Levy
- | New P1/2 trial: Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants (clinicaltrials.gov) - Oct 15, 2012
P1/2, N=140, Completed, Sponsor: Pauline Verdijk
- New P1 trial: Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults (clinicaltrials.gov) - Oct 15, 2012
P1, N=45, Completed, Sponsor: Pauline Verdijk
- |||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK
Trial completion: Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (clinicaltrials.gov) - Sep 26, 2012
P4, N=400, Completed, Sponsor: GlaxoSmithKline
N=900 --> 0 Active, not recruiting --> Completed
- ||| Enrollment change: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Sep 23, 2012
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed N=532 --> 278
- Clinical: UROHTLV: Urological Physical Therapy in HTLV-1 With Urinary Symptoms (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=20, Enrolling by invitation, Sponsor: Hospital Universitário Professor Edgard Santos
- |||| Trial completion: Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults (clinicaltrials.gov) - Jul 18, 2012
P4, N=212, Completed, Sponsor: GlaxoSmithKline
N=532 --> 278 Active, not recruiting --> Completed
- | Rotarix (rotavirus vaccine) / GSK
New P4 trial: Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines (clinicaltrials.gov) - Jun 10, 2012
P4, N=620, Completed, Sponsor: Program for Appropriate Technology in Health
- ||||||| Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
Trial completion: Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older (clinicaltrials.gov) - Jun 5, 2012
P3, N=342, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Priorix (MMR vaccine) / GSK
Trial completion: Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children (clinicaltrials.gov) - May 2, 2012
P3, N=387, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial completion: Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (clinicaltrials.gov) - Apr 12, 2012
P3, N=370, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) (clinicaltrials.gov) - Apr 3, 2012
P1, N=372, Recruiting, Sponsor: International Vaccine Institute
- dalfampridine / Generic mfg.
Trial initiation date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Mar 27, 2012
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Jul 2012
- New P3 trial: Diarrhea and Bivalent Oral Polio Vaccine Immunity (clinicaltrials.gov) - Mar 19, 2012
P3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
- || Enrollment change: A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=349, Completed, Sponsor: GlaxoSmithKline
Initiation date: Jan 2012 --> Jul 2012 N=600 --> 349
- ||| Trial completion: A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=349, Completed, Sponsor: GlaxoSmithKline
N=600 --> 349 Active, not recruiting --> Completed
- HEOR: Quality of Life in Adult Neurological Patients (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=70, Completed, Sponsor: Associação de Assistência a Criança Deficiente
- |||||||||| piracetam / Generic mfg.
New P3 trial: A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome (clinicaltrials.gov) - Mar 6, 2012
P3, N=120, Not yet recruiting, Sponsor: Biolab Sanus Farmaceutica
- ||||| New P4 trial: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Mar 5, 2012
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
- ||| Enrollment closed: Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine (clinicaltrials.gov) - Feb 21, 2012
P4, N=456, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- New P3 trial: Intravenous Immunoglobulins for Post-Polio Syndrome (clinicaltrials.gov) - Feb 16, 2012
P3, N=50, Completed, Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (clinicaltrials.gov) - Jan 12, 2012
P2, N=721, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || New P3 trial: The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) (clinicaltrials.gov) - Jan 5, 2012
P3, N=1200, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||| Trial completion: A Study of the Safety of IMOVAX Polio™ in China (clinicaltrials.gov) - Dec 11, 2011
P4, N=800, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (clinicaltrials.gov) - Dec 11, 2011
P3, N=455, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rotarix (rotavirus vaccine) / GSK
Trial completion: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar (clinicaltrials.gov) - Dec 11, 2011
P3, N=1375, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine (clinicaltrials.gov) - Nov 17, 2011
P4, N=456, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- pentoxifylline / Generic mfg.
New P3 trial: Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases (clinicaltrials.gov) - Nov 10, 2011
P3, N=48, Active, not recruiting, Sponsor: Hospital Universit
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Rotarix (rotavirus vaccine) / GSK
Trial completion: Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (clinicaltrials.gov) - Oct 20, 2011
P2, N=480, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (clinicaltrials.gov) - Oct 19, 2011
P3, N=80, Completed, Sponsor: GlaxoSmithKline
- |||||||||| Pediarix (diphtheria, tetanus toxoids and acellular pertussis adsorbed, hepatitis b and inactivated poliovirus vaccine) / GSK, Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (clinicaltrials.gov) - Oct 19, 2011
P3, N=440, Completed, Sponsor: GlaxoSmithKline
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P4 trial: Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (clinicaltrials.gov) - Oct 12, 2011
P4, N=494, Completed, Sponsor: GlaxoSmithKline
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
New P2 trial: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (clinicaltrials.gov) - Oct 12, 2011
P2, N=312, Completed, Sponsor: GlaxoSmithKline